Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study

Study limitation reported by the research below: “The 'practice changing' impact flag is applied cautiously — this is a retrospective observational study with IPTW adjustment, not a head-to-head RCT; residual confounding cannot be excluded.”